每(mei)經AI快訊，博(bo)(bo)瑞醫藥（SH 688166，收盤價：58.06元(yuan)(yuan)）9月26日(ri)晚間發(fa)布公(gong)(gong)(gong)告稱，基于(yu)公(gong)(gong)(gong)司(si)的(de)(de)(de)戰(zhan)略(lve)發(fa)展(zhan)規劃以(yi)及(ji)公(gong)(gong)(gong)司(si)全(quan)資(zi)(zi)子公(gong)(gong)(gong)司(si)博(bo)(bo)瑞泰(tai)興(xing)(xing)的(de)(de)(de)經營發(fa)展(zhan)需(xu)要，博(bo)(bo)瑞泰(tai)興(xing)(xing)擬通過增(zeng)(zeng)資(zi)(zi)擴股(gu)(gu)方(fang)式引入投資(zi)(zi)者蘇州(zhou)信(xin)博(bo)(bo)瑞，蘇州(zhou)信(xin)博(bo)(bo)瑞以(yi)人民幣1.98億元(yuan)(yuan)認購(gou)博(bo)(bo)瑞泰(tai)興(xing)(xing)新增(zeng)(zeng)注(zhu)冊資(zi)(zi)本(ben)(ben)2268.05萬元(yuan)(yuan)，其余約1.75億元(yuan)(yuan)計入博(bo)(bo)瑞泰(tai)興(xing)(xing)資(zi)(zi)本(ben)(ben)公(gong)(gong)(gong)積(ji)，公(gong)(gong)(gong)司(si)放棄本(ben)(ben)次(ci)增(zeng)(zeng)資(zi)(zi)的(de)(de)(de)優先認購(gou)權。本(ben)(ben)次(ci)增(zeng)(zeng)資(zi)(zi)完(wan)成(cheng)后(hou)，博(bo)(bo)瑞泰(tai)興(xing)(xing)的(de)(de)(de)注(zhu)冊資(zi)(zi)本(ben)(ben)將(jiang)由(you)5500萬元(yuan)(yuan)增(zeng)(zeng)加至7768.05萬元(yuan)(yuan)，公(gong)(gong)(gong)司(si)直(zhi)接持(chi)有博(bo)(bo)瑞泰(tai)興(xing)(xing)的(de)(de)(de)股(gu)(gu)權比例將(jiang)由(you)100%變更為(wei)70.8%，博(bo)(bo)瑞泰(tai)興(xing)(xing)仍屬于(yu)公(gong)(gong)(gong)司(si)合并報表范圍內的(de)(de)(de)控股(gu)(gu)子公(gong)(gong)(gong)司(si)。本(ben)(ben)次(ci)交易不(bu)構(gou)成(cheng)關(guan)聯交易，亦(yi)不(bu)構(gou)成(cheng)《上市公(gong)(gong)(gong)司(si)重大資(zi)(zi)產重組(zu)管理(li)辦法》規定的(de)(de)(de)重大資(zi)(zi)產重組(zu)。

2024年1至12月份，博瑞醫藥(yao)的(de)營業收(shou)入構成(cheng)為：醫藥(yao)制造業占(zhan)比97.33%，其他業務占(zhan)比2.67%。

截至(zhi)發稿，博瑞醫藥(yao)市值為245億(yi)元。

每經頭(tou)條(tiao)（nbdtoutiao）——

（記者 曾健輝）

免責聲明：本文內容與數據僅(jin)供參考，不構成投(tou)資建議，使用前請核實(shi)。據此(ci)操作，風險(xian)自擔。